Literature DB >> 14726761

Suppression of graft-versus-host disease by naturally occurring regulatory T cells.

Defu Zeng1, Fengshuo Lan, Petra Hoffmann, Samuel Strober.   

Abstract

Studies of graft-versus-host disease after allogeneic bone marrow transplantation have shown that there are subsets of freshly isolated donor T cells that induce the disease and subsets that suppress the disease. The balance of subsets in the graft determines disease severity. The authors' work on the nature of the regulatory-suppressor T cells and their mechanisms of action is summarized in this article.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726761     DOI: 10.1097/01.TP.0000106475.38978.11

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Adoptive T Regulatory Cell Therapy for Tolerance Induction.

Authors:  Cecilia Cabello-Kindelan; Shane Mackey; Allison L Bayer
Journal:  Curr Transplant Rep       Date:  2015-06-01

2.  CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Authors:  Anna Hryniewicz; Adriano Boasso; Yvette Edghill-Smith; Monica Vaccari; Dietmar Fuchs; David Venzon; Janos Nacsa; Michael R Betts; Wen-Po Tsai; Jean-Michel Heraud; Brigitte Beer; Diann Blanset; Claire Chougnet; Israel Lowy; Gene M Shearer; Genoveffa Franchini
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

3.  Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI.

Authors:  Nainong Li; Ying Chen; Wei He; Tangsheng Yi; Dongchang Zhao; Chunyan Zhang; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

4.  Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches.

Authors:  Ana Hernandez; Melissa Burger; Bonnie B Blomberg; William A Ross; Jeffrey J Gaynor; Inna Lindner; Robert Cirocco; James M Mathew; Manuel Carreno; Yidi Jin; Kelvin P Lee; Violet Esquenazi; Joshua Miller
Journal:  Hum Immunol       Date:  2007-07-02       Impact factor: 2.850

5.  In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease.

Authors:  Dongchang Zhao; Chunyan Zhang; Tangsheng Yi; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-06-12       Impact factor: 22.113

Review 6.  A Look into Stem Cell Therapy: Exploring the Options for Treatment of Ischemic Stroke.

Authors:  Cesar Reis; Michael Wilkinson; Haley Reis; Onat Akyol; Vadim Gospodarev; Camila Araujo; Sheng Chen; John H Zhang
Journal:  Stem Cells Int       Date:  2017-10-22       Impact factor: 5.443

Review 7.  An Essential Role of Innate Lymphoid Cells in the Pathophysiology of Graft-vs.-Host Disease.

Authors:  Liang Shao; Shan Pan; Qiu-Ping Zhang; Muhammad Jamal; Lu-Hua Chen; Qian Yin; Ying-Jie Wu; Jie Xiong; Rui-Jing Xiao; Yok-Lam Kwong; Fu-Ling Zhou; Albert K W Lie
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

Review 8.  The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous.

Authors:  Jia-Ming Chen; Qiao-Yi Huang; Yun-Xia Zhao; Wei-Hong Chen; Shu Lin; Qi-Yang Shi
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.